Harbin Pharmaceutical Group Co., Ltd. Class ASSE: 600664

Announcement on Progress in Technology Transfer (Entrustment) Contract Signed by a Wholly-owned Subsidiary and Entry of Daprodustat Tablets into Phase III Clinical Trial (Confirmatory Clinical Study)

· Issued by Harbin Pharmaceutical Group Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Progress in Technology Transfer (Entrustment) Contract Signed by a Wholly-owned Subsidiary and Entry of Daprodustat Tablets into Phase III Clinical Trial (Confirmatory Clinical Study)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Earlier from Harbin Pharmaceutical Group Co., Ltd. Class A

All Harbin Pharmaceutical Group Co., Ltd. Class A news releases